<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04342793</url>
  </required_header>
  <id_info>
    <org_study_id>AL101-NASH</org_study_id>
    <nct_id>NCT04342793</nct_id>
  </id_info>
  <brief_title>A Study to Evaluate the Efficacy and Safety of ALS-L1023 in Subjects With NASH</brief_title>
  <official_title>A Multicenter, Randomized, Double-blind, Placebo-controlled Phase 2a Study to Explore the Safety and Efficacy of ALS-L1023 in Patients With Non-alcoholic Steatohepatitis (NASH)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>AngioLab, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>AngioLab, Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The main objective of this study is to evaluate safety and efficacy of ALS-L1023 in patients
      with Non-alcoholic steatohepatitis
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Besides the main objectives, there are other objectives as follows:

        1. To evaluate efficacy of ALS-L1023 for liver fibrosis and steatosis by noninvasive
           imaging biomarker MRI-PDFF and MRE

        2. To determine optimized dose of ALS-L1023 in NASH disease
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">December 4, 2019</start_date>
  <completion_date type="Anticipated">December 4, 2020</completion_date>
  <primary_completion_date type="Anticipated">December 4, 2020</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in liver fat percentage measured by MRI-PDFF</measure>
    <time_frame>baseline, 24 weeks</time_frame>
    <description>Liver fat is measured by MRI-PDFF</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in liver fibrosis measured by MRE</measure>
    <time_frame>baseline, 24 weeks</time_frame>
    <description>Liver fibrosis is measured by Magnetic Resonance Enterography</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in visceral fat area measured by MRI</measure>
    <time_frame>baseline, 24weeks</time_frame>
    <description>Visceral fat area is measured by MRI</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Changes in serum concentrations of ALT and AST</measure>
    <time_frame>baseline, 24weeks</time_frame>
    <description>ALT and AST concentrations in serum are measured</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in serum concentration of Pro-C3</measure>
    <time_frame>baseline, 24weeks</time_frame>
    <description>Pro-C3 concentration in serum is measured</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in serum concentration of CK-18</measure>
    <time_frame>baseline, 24weeks</time_frame>
    <description>CK-18 concentration in serum is measured</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in insulin sensitivity determined by HOMA-IR</measure>
    <time_frame>baseline, 24weeks</time_frame>
    <description>Insulin sensitivity is determined by Homeostatic Model Assessment for Insulin Resistance</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in serum concentration of Leptin</measure>
    <time_frame>baseline, 24weeks</time_frame>
    <description>Concentration of Leptin in serum is measured</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in serum concentrations of ALT and AST</measure>
    <time_frame>baseline, 8weeks, 16weeks</time_frame>
    <description>ALT and AST concentrations in serum are measured</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in serum concentrations of TG and TC</measure>
    <time_frame>baseline, 8weeks, 16weeks, 24weeks</time_frame>
    <description>Triglyceride and Total Cholesterol concentrations in serum are measured</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change of NAFLD fibrosis score(NFS)</measure>
    <time_frame>baseline, 8weeks, 16weeks, 24weeks</time_frame>
    <description>NFS is measured</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in serum concentration of Ghrelin</measure>
    <time_frame>baseline, 24weeks</time_frame>
    <description>Concentration of Ghrelin in serum is measured</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in serum concentration of Adiponection</measure>
    <time_frame>baseline, 24weeks</time_frame>
    <description>Concentration of Adiponection in serum is measured</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">60</enrollment>
  <condition>Nonalcoholic Steatohepatitis</condition>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo</description>
  </arm_group>
  <arm_group>
    <arm_group_label>ALS-L1023 1,200mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>ALS-L1023 600mg twice a day</description>
  </arm_group>
  <arm_group>
    <arm_group_label>ALS-L1023 1,800mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>ALS-L1023 900mg twice a day</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo oral tablet</intervention_name>
    <description>Placebo</description>
    <arm_group_label>Placebo</arm_group_label>
    <other_name>Placebo</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ALS-L1023 1,200mg</intervention_name>
    <description>ALS-L1023</description>
    <arm_group_label>ALS-L1023 1,200mg</arm_group_label>
    <other_name>ALS-L1023 tablet</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ALS-L1023 1,800mg</intervention_name>
    <description>ALS-L1023</description>
    <arm_group_label>ALS-L1023 1,800mg</arm_group_label>
    <other_name>ALS-L1023 tablet</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Men or women ages 19 and over, under 75 years of age

          -  Patients diagnosed with NAFLD on abdominal ultrasonography and MRI

          -  Patients show presence of hepatic fat fraction as defined by ≥ 8% on MRI-PDFF and
             liver stiffness as defined by ≥ 2.5 kPa on MRE at Screening

        Exclusion Criteria:

          -  Any subject with current, significant alcohol consumption or a history of significant
             alcohol consumption for a period of more than 3 consecutive months any time within 2
             year prior to screening will be excluded

          -  Chronic liver disease (including hemochromatosis, liver cancer, autoimmune liver
             disease, viral hepatitis A, B, alcoholic liver disease

          -  Uncontrolled diabetes mellitus as defined by a HbA1c ≥ 9.0％ at Screening

          -  Patients who are allergic or hypersensitive to the drug or its constituents

          -  Pregnant or lactating women
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>19 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Dae Won Jun, Ph. D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hanyang University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Min-Young Kim</last_name>
    <phone>+82-42-867-5785</phone>
    <email>angiolab@angiolab.co.kr</email>
  </overall_contact>
  <location>
    <facility>
      <name>Hanyang University Seoul Hospital</name>
      <address>
        <city>Seoul</city>
        <zip>04763</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Dae Won Jun</last_name>
      <phone>+82-02-2290-8338</phone>
      <email>noshin@hanyang.ac.kr</email>
    </contact>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>April 2020</verification_date>
  <study_first_submitted>April 6, 2020</study_first_submitted>
  <study_first_submitted_qc>April 10, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">April 13, 2020</study_first_posted>
  <last_update_submitted>April 10, 2020</last_update_submitted>
  <last_update_submitted_qc>April 10, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">April 13, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Fatty Liver</mesh_term>
    <mesh_term>Non-alcoholic Fatty Liver Disease</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

